Chronic obstructive pulmonary disease in the light of new guidelines – brief summary of phenotypically oriented guidelines for non‑pulmonary physicans

Czech version

Authors: V. Koblížek ¹; J. Chlumský ²; V. Zindr ³; K. Neumannová ^4,5; J. Zatloukal ⁴; V. Sedlák ¹; J. Kociánová ⁶; J. Zatloukal ⁷; B. Novotná ¹
Authors‘ workplace: Plicní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MU Dr. František Salajka, CSc. 2 Pneumologická klinika 1. lékařské fakulty UK a Thomayerovy nemocnice Praha, přednosta prof. MU Dr. Jiří Homolka, DrSc. 3 Plicní ordinace Karlovy Vary4 ¹
Published in: Vnitř Lék 2013; 59(6): 505-514
Category: Guidelines

Overview

Introduction:
COPD is a global health and social problem. Morbidity and mortality increases in the Czech Republic. There are currently several global statements and strategies.

Methods:
The Czech Pneumological and Phthisiological Society (CPFS) at the end of 2011 mandated the Section of bronchial obstruction in drafting national guidelines concerning the stable COPD. Subsequently, this document was discussed during the National Consensus Conference (COPD forum) in November 2012 and presented at series of local workshops and national conferences. National guidelines has been subject to a review and eventually posted on the website for another round of comments.

Diagnosis:
A modern approach to COPD is a view of the patient through the pulmonary function, symptoms, exacerbation rates and the presence of specific phenotypes. CPFS identified six clinically relevant phenotypes: frequent exacerbators, COPD and asthma overlap, COPD and bronchiectasis overlap, emphysematic phenotype, bronchitic phenotype and phenotype of pulmonary cachexia.

Treatement:
Treatment recommendations can be divided into four elementary steps: the first step is the Elimination of all risks factors. The second one is the Standard therapy including in particular inhaled bronchodilators, pulmonary rehabilitation, and treatment of severe comorbidities. The third step is the Targeted therapy centered on clinical phenotypes of COPD. The final fourth step is the treatment of respiratory insufficiency and palliative care of the terminal COPD.

Conclusion:
The optimal treatment of COPD requires a personalized approach to the patient.

Key words:
COPD phenotypes – personalized medicine – national guidelines

Sources

1. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemilogical data in Europe: systematic review. BMC Med 2011; 9: 7.

2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613– 620.

3. Lamprecht B, Mahringer A, Soriano JB et al. Is spirometry properly used to diagnose COPD? Results from the BOLD study in Salzburg, Austria: a population‑based analytical study. Prim Care Respir J 2013; 22: 195– 200.

4. Malý M, Zvolský M, Rozborilová E et al. Respiratory Mortality in Czech and Slovak Republics in the year 2011. Stud Pneumol Phtiseol 2013; 79. In press.

5. Vondra V. Úmrtnost na CHOPN v letech 1996– 2005 se zdvojnásobila. Stud Pneumol Phtiseol 2007; 73: 75.

6. Institute of Medical Information Services. Tuberculosis and respiratory diseases 2011. 2012 Nov [cited 2013 Mar 2]. Available from: http:/ / www.uzis.cz/ katalog/ zdravotnicka‑ statistika/ tuberkuloza‑ respiracni‑ nemoci.

7. Qaseem A, Wilt TJ, Weinberger SE et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update for the ACP, ACCP, ATS and ERS. Ann Intern Med 2011; 155: 179– 191.

8. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. 2013 Feb [cited 2013 Mar 2]. Available from: http:/ / www.goldcopd.org/ uploads/ users/ /files/ GOLD_Report_2013_Feb20.pdf.

9. Miravitlles M, Soler‑ Cataluña JJ, Calle M et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012; 48: 247– 257.

10. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (updated) Clinical guidelines CG101. 2013 Mar [cited 2013 Apr 2]. Available from: http:/ / www.nice.org.uk/ CG101.

11. Celli BR. Update on the management of COPD. Chest 2008; 133: 1451– 1462.

12. Česká pneumologická a ftizeologická společnost. Doporučený postup pro diagnostiku a léčbu CHOPN. 2013 Feb [cited 2013 May 4]. Available from: http:/ / www.pneumologie.cz/ aktualne/ doc/ Standard%20verze%2021.1.pdf.

13. Hooper R, Burney P, Vollmer WM et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012; 39: 1343– 1353.

14. Lamprecht B, McBurnie MA, Vollmer WM et al. COPD in never smokers: results from the population‑based burden of obstructive lung disease study. Chest 2011; 139: 752– 763.

15. Cho MH, Castaldi PJ, Wan ES et al. A genome‑ wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2012; 21: 947– 957.

16. Celli BR, Cote CG, Marin JM et al. The body‑mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005– 1012.

17. O’Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832– 840.

18. Stridsman C, Lindberg A, Skär L. Fatigue in chronic obstructive pulmonary disease: a qualitative study of people’s experiences. Scand J Caring Sci 2013. In press.

19. Koblizek V, Tomsova M, Cermakova E et al. Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype. Rhinology 2011; 49: 397– 406.

20. Bakke PS, Ronmark E, Eagan T et al. Recommendations for epidemiological studies on COPD. Eur Respir J 2011; 38: 1261– 1277.

21. Miravitlles M, Calle M, Soler‑ Cataluña JJ. Clinical phenotypes of COPD. Identification, definition and implications for quidelines. Arch Bronconeumol 2012; 48: 86– 98.

22. Floto RA, Haworth CS. Bronchiectasis. European Respiratory Monograph. Sheffield: European Respiratory Society 2011.

23. Pasteur MC, Bilton D, Hill AT et al. British Thoracic Society guideline for non‑CF bronchiectasis. Thorax 2010; 65 (Suppl 1): i1– i59.

24. Aaron SD, Donaldson GC, Whitmore GA et al. Time course and pattern of COPD exacerbation onset. Thorax 2012; 67: 238– 243.

25. George C, Zermansky W, Hurst JR. Frequent exacerbations in chronic obstructive pulmonary disease. BMJ 2011; 342: d1434.

26. Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 625– 626.

27. Sanchez FF, Faganello MM, Tanni SE et al. Anthropometric midarm measurements can detect systemic fat‑free mass depletion in patients with chronic obstructive pulmonary disease. Braz J Med Biol Res 2011; 44: 453– 459.

28. Schleich FN, Seidel L, Sele J et al. Exhaled nitric oxide tresholds associated with a sputum eosinophil count ≥ 3% in a cohort of unselected patients with asthma. Thorax 2010; 65: 1039– 1044.

29. Izquierdo‑ Alonso JL, Rodriguez‑ Gonzálezmoro JM, de Lucas‑ Ramos P et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013; 107: 724– 731.

30. Vanfleteren LE, Spruit MA, Groenen M et al.Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728– 735.

31. Clarenbach CF, Thurnheer R, Kohler M et al. Vascular dysfunction in chronic obstructive pulmonary disease: current evidence and perspectives. Expert Rev Respir Med 2012; 6: 37– 43.

32. Sode B, Dahl M, Nordestgaar BG. Myocardial infarction and other co‑ morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011; 32: 2365– 2375.

33. Nava S, Sturani C, Hartl S et al. End‑of‑life decision – making in respiratory intermediate care units: a European survey. ERS TASK FORCE. Eur Respir J 2007; 30: 156– 164.

34. Lanken PN, Terry PB, DeLisser HM et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177: 912– 927.

35. Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948– 968.

36. Gonem S, Raj V, Wardlaw J et al. Phenotyping airways disease: an A to E approach. Clin Exper Allergy 2012; 42: 1664– 1683.

37. Jones P, Adamek L, Nadeau G et al. Comparisons of health status scores with MRC grades in a primary care COPD population: implications for the new GOLD 2011 classification. Eur Respir J 2012. In press.

38. Han M, Dransfield M, Curran‑ Everett D et al. Characteristics of GOLD 2011 grading system in the COPDGene cohort. In: European Respiratory Society Annual Congress Vienna 2012 1– 5 Sep. Eur Respir J 2012; 40 (Suppl 56): 1646.

39. Lange P, Marott JL, Vestbo J et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186: 975– 981.

40. Anthoniesen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5‑year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233– 239.

41. Lee PN, Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med 2010; 8: 84.

42. Vestbo J, Edwards LD, Scanlon PD et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184– 1192.

43. Decramer M, Celli BR, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT) a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171– 1178.

44. Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on the rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332– 338.

45. Jenkins CR, Jones PW, Calverley PM et al. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‑ controlled TORCH study. Respir Res 2009; 10: 59.

46. Laube BL, Janssens HM, Jongh FH et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J2011; 37: 1308– 1331.

47. Mahler DA, D’Urzo A, Bateman ED et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilatation compared with tiotropium alone: a randomised, double‑blind comparison. Thorax 2012; 67: 781– 788.

48. Tashkin DP, Fabbri LM. Long‑acting beta‑agonist in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149.

49. Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‑blind, parallel‑ group study. Lancet 2013. In press.

50. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbation of COPD. N Engl J Med 2011; 364: 1093– 1103.

51. Calverley PM, Anderson JA, Celli BR et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775– 789.

52. Donohue JF, Fogarty LM, Lotvall J et al. Once‑ daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155– 162.

53. Kornmann O, Dahl R, Centanni S et al. Once‑ daily indacaterol versus twice‑ daily salmeterol for COPD: a placebo‑ controlled comparison. Eur Respir J 2011; 37: 273– 279.

54. Welte T, Miravitlles M, Hernandez P et al. Efficacy and tolerability of budesonide/ formoterol addend to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741– 750.

55. Singh S, Loke YK, Enright PL et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta‑analysis of randomised controlled trials. BMJ 2011; 342: d3215.

56. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium the FDA’s conclusions. N Engl J Med 2010; 363: 1097– 1099.

57. Kesten S, Casaburi R, Kukafka D et al. Improvement in self‑ reported exercise participation with combination of tiotropium and and rehabilitative exercise training in COPD patients. Int J Chron Obstr Pulmon Dis 2008; 3: 127– 136.

58. Calverley PM, Stockley RA, Seemungal TA et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505– 512.

59. Ferguson GT, Calverley PM, Anderson JA et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TORCH study. Chest 2009; 136: 1456– 1465.

60. Centers for disease control and prevention. Prevention and control of seasonal influenza vaccines. Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Morb Mortal Wkly Rep 2009; 58: 1– 52.

61. Centers for disease control and prevention. Recommended adult immunization schedule. United States 2010. MMWR Morb Mortal Wkly Rep 2011; 60: 1– 4.

62. Hodgkin JE, Celli BR, Connors GL. Pulmonary rehabilitation. Guidelines to success. St. Louis, Missouri: Mosby Elsevier 2009.

63. Stone RA, Lowe D, Potter JM et al. Managing patients with COPD exacerbation: does age matter? Age Ageing 2012; 41: 461– 468.

64. Kerstjens H, Engel M, Dahl R et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198– 1207.

65. Thomsen M, Nordestgaard BG, Sethi AA et al. 2‑adrenergic receptor polymorphisms, asthma and COPD: two large population‑based studies. Eur Respir J 2012; 39: 558– 566.

66. Rossi A, Kristufek P, Levine BE et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‑ release theophylline in the treatment of COPD. Chest 2002; 121: 1058– 1069.

67. Grootendorst DC, Gauw SA, Verhoosel RM et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081– 1087.

68. Rabe KF. Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Resp Med 2010; 4: 543– 555.

69. Wood A, Stockley R. Alpha one antitrypsin deficiency: from gene to treatment. Respiration 2007; 74: 481– 492.

70. Wood A, Tan S, Stockley R. Chronic obstructive pulmonary disease: towards pharmacogenetics. Genome Med 2009; 1: 112.

71. Benditt JO. Surgical options for patients with COPD: sorting out the choices. Respir Care 2006; 51: 173– 182.

72. Martinez FJ, Chang AC, Chan KM. Surgical Therapy for COPD. In: Rennard SI, Rodríguez‑ Roisin S, Huchon G et al (eds). Clinical Management of Chronic Obstructive Pulmonary Disease. New York: Informa, Healthcare 2008: 435– 474.

73. Criner GJ, Cordova F, Sternberg AL et al. The National Emphysema Treatment Trial (NETT): Part I: Lessons learned about emphysema. Am J Respir Crit Care Med 2011; 184: 763– 770.

74. Criner GJ, Cordova F, Sternberg AL et al. The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med 2011; 184: 881– 893.

75. Herth F, Noppen M, Valipour A et al. Efficacy predictors of lung volumereduction with Zephyr valves in a Europeancohort. Eur Respir J 2012; 39: 1334– 1342.

76. Herth F, Eberhardt R, Gompelmann D et al. Radiological and clinical outcomes of using ChartisTM to plan endobronchial valve treatment. Eur Respir J 2013; 41: 302– 308.

77. Anker S, John M, Pedersen P et al. ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. Clin Nutr 2006; 25: 311– 318.

78. Anker S, Laviano A, Filippatos G et al. ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr 2009; 28: 455– 460.

79. Elborn S, Tunney MM. Macrolide and bronchiectasis. Clinical benefit with a resistance price. JAMA 2013; 309: 1295– 1296.

80. Pannu KD. Azithromycin 250 mg daily reduces exacerbation frequency and improves quality of life in selected COPD patients. Thorax 2012; 67: 391.

81. Peters J, Anzueto A. Azithromycin once daily for 1 year reduced acute COPD exacerbations. Ann Intern Med 2012; 156: JC1– JC10.

82. Pomares X, Montón C, Espasa M et al. Long‑term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstr Pulmon Dis 2011; 6: 449– 456.

83. Albert RK, Connett J, Bailey WC. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689– 698.

84. Uzun S, Djamin RS, Kluytmans J et al. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. Trials 2012; 13: 82.

85. Altenburg J, de Graaff CS, Stienstra Y et al. Effect of azitromycin maintenance treatment on infectious exacerbations among patients with non‑cystic fibrosis bronchiectasis. The BAT randomized controlled trial. JAMA 2013; 309: 1251– 1259.

86. Sethi S, Jones PW, Theron MS et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10.

87. Hobbs K, Brown D. Consider adding this drug to fight COPD that‘s severe. J Fam Pract 2012; 61: 414– 416.

88. Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev 2010; 19: 134– 140.

89. Moretti M, Bottrighi P, Dallari R et al. The effect of long‑term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004; 30: 143– 152.

90. Czech Pneumological and Phthisiological Society. Guidelines for indication of home long term oxygen therapy 2013. 2013 Apr [cited 2013 Apr 17]. Available from: http:/ / www.pneumologie.cz/ odborne/ doc/ Standard%20DDOT‑ %20final.pdf.

91. Somfay A, Porszasz J, Lee SM et al. Dose‑response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001; 18: 77– 84.

92. Edvardsen A, AkerØ´ A, Christensen CC et al.Air travel and COPD: A new algorithm for pre‑flight evaluation. Thorax 2012; 67: 964– 969.

93. Dreher M, Storre JH, Schmoor C et al. High intensity versus low‑ intensity non‑invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax 2010; 65: 303– 308.

94. Duiverman ML, Wempe JB, Bladder G et al. Nocturnal non‑invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax 2008; 63: 1052– 1057.

95. Duiverman ML, Wempe JB, Bladder G et al. Two‑year home‑based nocturnal non‑invasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respir Res 2011; 12: 112.

96. Au DH, Curtis JR. Providing Palliative and End‑of‑ Life Care for Patients with COPD. In: Rennard SI, Rodríguez‑ Roisin S, Huchon G et al (eds). Clinical Management of Chronic Obstructive Pulmonary Disease. New York: Informa, Healthcare 2008: 515– 529.

97. Kamal AH, Maguire JM, Wheeler JL et al. Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med 2012; 15: 106– 114.

98. Uronis HE, Currow DC, Abernethy AP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstr Pulmon Dis 2006; 1: 289– 304.